Research programme: anti-cancer immunotherapeutics - QUE OncologyAlternative Names: Q 204
Latest Information Update: 08 Jun 2016
At a glance
- Originator QUE Oncology
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malignant melanoma
Most Recent Events
- 08 Jun 2016 Preclinical trials in Malignant melanoma in USA (unspecified route) before June 2016